Market news

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the P

Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for t

Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.

PHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted a non-qualified stock option award to purchase 146,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option award was granted outside of the Context Therapeu

PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index measures the performance of the largest 3,000 publicly tra

Context Therapeutics Inc. (NASDAQ:CNTX) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. A sharp stock selloff tied to early clinical data has drawn a series of analysts defending the shares as oversold. The stock is down nearly 60% year-to-date. On June 16, 2026, Maxim analyst Jason McCarthy lowered […]